by Nathaniel Harding | Apr 26, 2024 | Blog
Sensulin Biotech, an Oklahoma startup, is bringing the lowest-cost Smart Insulin to the market. Mike Moradi, CEO of Sensulin and General Partner of Cortado Ventures, aims to reduce the burden of diabetes and change lives by creating innovative opportunities for their...
by Nathaniel Harding | Mar 25, 2024 | Blog
Read the full story here Authored by Susan Morning, Cortado Ventures General Partner In an industry where women are still significantly underrepresented with women representing just 8.6% of all venture capitalists and 8% of firm partners across the country, and...
by Nathaniel Harding | Mar 11, 2024 | Blog
Read Why We Invested in Cadenza Bio on our Medium page. Authored by Mansi Patel, Cortado Ventures Analyst Novel therapeutic drugs for the treatment of neurodegenerative diseases Cortado Ventures is thrilled to have recently invested in Cadenza Bio, an...
by Nathaniel Harding | Feb 22, 2024 | Blog
A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad Read the full story here Cortado is thrilled to invest in CorriXR Therapeutics, an early-stage biotech company commercializing a platform gene editing technology with a first-use case in oncology. The...
by Nathaniel Harding | Feb 1, 2024 | Blog
2023 Lookback for Cortado Ventures — Read the full story here At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and...
by Cortado Ventures Media | Jan 29, 2024 | Blog, Media, Portfolio Companies
Why We Invested: Lumata Health Pioneering Next-Generation Eye Care Authored by Cody Merrill At Cortado Ventures, we are in the venture capital business of maximizing risk-adjusted returns with high-potential, early-stage startups. We seek...
